Similar results were reported by Taubmann et al. [12] when they used CD19-targeted CAR-T-cell therapy for a 32-year-old female with severe refractory lupus who achieved low disease activity at 3 months. The gene discussed is CD19; the disease is systemic lupus erythematosus.